To successfully transition from paid and value-based care, providers should prioritize superior care management, strong medical guidance, disciplined financial management and better consumer experience. Participants reflected on what is needed to make VBCs close to reality from the point of view of each stakeholder, pragmatic approaches to overcoming barriers for VBCs and where we can begin to make VBCs a mainstream. The link between value and bio-scientific treatments through patient outcomes is on the horizon. Drug pricing remains in the public spotlight. Companies that over-concentrate likely regulatory mandates and are now beginning the transition will be a competitive step compared to those that are lagging behind. Common Savings Second, Ms Macias has outlined common savings arrangements that allow both the payer and the trader to save money on the basis of cost-cutting measures. Not only does this model encourage payers and suppliers to reduce costs, but it also provides additional benefits to both parties. According to Macias, payers find common savings attractive because they would not normally see that money, and providers find it attractive because they are protected from disastrous risks and have more control over patient experience and engagement. But despite these and other significant examples – and despite signs of a recent increase in the number of reported and unreported agreements – the use of VBAs remains limited, and many VBAs actually provide limited value. Deloitte has the breadth and depth of skills to help the health and life sciences sectors overcome these barriers.
Our value-based care practice, recognized several times by KLAS as a leader in our field, serves as a trusted intermediary for multi-party contracts. We take a healthy mix of inter-functional perspectives, from actuaries to data scientists, from industrial consultants to technologists, to facilitate the necessary changes in volume to value-based sourcing. Our approach below includes a contracting strategy based on value and implementation of agreements in an end-to-end lifecycle. For these reasons, it doesn`t make much sense to make a value-based agreement, just to say that you have a value-based agreement. So when can you create enough value for VBAs to do sensible things – and how to deal with them? Risk Share under an Alternative Payment Model The fourth and final opportunity to enter into value-based contracts with a supplier is a process in which both the hospital and the supplier are at risk.